Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2019, Article ID 8393769, 11 pages
https://doi.org/10.1155/2019/8393769
Research Article

Identification of Cell-Free Circulating MicroRNAs for the Detection of Early Breast Cancer and Molecular Subtyping

1Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
2Department of Clinical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
3Department of Mastology and Breast Reconstruction, Barretos Cancer Hospital, Barretos, Brazil
4Tumor Biobank, Barretos Cancer Hospital, Barretos, São Paulo, Brazil
5Department of Basic and Oral Biology, School of Dentistry of Ribeirão Preto, University of São Paulo, Brazil
6Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal
7ICVS/3B’s-PT Government Associate Laboratory, Braga/Guimarães, Portugal
8Barretos School of Health Sciences, FACISB, Barretos, São Paulo, Brazil

Correspondence should be addressed to Marcia M. C. Marques; moc.liamg@arievlismcmm

Received 14 February 2019; Revised 15 April 2019; Accepted 19 June 2019; Published 8 August 2019

Guest Editor: Chia-Jung Li

Copyright © 2019 Karen C. B. Souza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Fact Sheets by Cancer,” 2018, http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
  2. “AJCC - American Joint Committee on Cancer,” 2017, https://cancerstaging.org/Pages/default.aspx.
  3. “American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer,” Journal of Oncology Practice, vol. 3, no. 6, pp. 336–339, 2007. View at Publisher · View at Google Scholar
  4. N. T. Brewer, T. Salz, and S. E. Lillie, “Systematic review: the long-term effects of false-positive mammograms,” Annals of Internal Medicine, vol. 146, no. 7, pp. 502–510, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. P. C. Sharp, R. Michielutte, R. Freimanis, L. Cunningham, J. Spangler, and V. Burnette, “Reported pain following mammography screening,” JAMA Internal Medicine, vol. 163, no. 7, pp. 833–836, 2003. View at Publisher · View at Google Scholar
  6. M. Duffy, N. Harbeck, M. Nap et al., “Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM),” European Journal of Cancer, vol. 75, pp. 284–298, 2017. View at Publisher · View at Google Scholar
  7. G. Siravegna, S. Marsoni, S. Siena, and A. Bardelli, “Integrating liquid biopsies into the management of cancer,” Nature Reviews Clinical Oncology, vol. 14, no. 9, pp. 531–548, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Y. Shin, J. M. Siu, I. Cheuk, E. K. Ng, and A. Kwong, “Circulating cell-free miRNAs as biomarker for triple-negative breast cancer,” British Journal of Cancer, vol. 112, no. 11, pp. 1751–1759, 2015. View at Publisher · View at Google Scholar
  9. J. Wittmann and H.-M. Jäck, “Serum microRNAs as powerful cancer biomarkers,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1806, no. 2, pp. 200–207, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Roth, B. Rack, V. Müller, W. Janni, K. Pantel, and H. Schwarzenbach, “Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer,” Breast Cancer Research, vol. 12, no. 6, Article ID R90, 2010. View at Publisher · View at Google Scholar
  11. M. Chan, C. S. Liaw, S. M. Ji et al., “Identification of circulating microrna signatures for breast cancer detection,” Clinical Cancer Research, vol. 19, no. 16, pp. 4477–4487, 2013. View at Publisher · View at Google Scholar
  12. M. Marques, A. Evangelista, T. Macedo et al., “Expression of tumor suppressors miR-195 and let-7a as potential biomarkers of invasive breast cancer,” Clinics, vol. 73, Article ID e184, 2018. View at Publisher · View at Google Scholar
  13. D. Huo, W. M. Clayton, T. F. Yoshimatsu, J. Chen, and O. I. Olopade, “Identification of a circulating MicroRNA signature to distinguish recurrence in breast cancer patients,” Oncotarget, vol. 7, pp. 55231–55248, 2016. View at Publisher · View at Google Scholar
  14. I. Stückrath, B. Rack, W. Janni, B. Jäger, K. Pantel, and H. Schwarzenbach, “Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients,” Oncotarget, vol. 6, no. 15, pp. 13387–13401, 2015. View at Publisher · View at Google Scholar
  15. F. Wang, Z. Zheng, J. Guo, and X. Ding, “Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor,” Gynecologic Oncology, vol. 119, no. 3, pp. 586–593, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. H. M. Heneghan, N. Miller, A. J. Lowery, K. J. Sweeney, J. Newell, and M. J. Kerin, “Circulating microRNAs as novel minimally invasive biomarkers for breast cancer,” Annals of Surgery, vol. 251, no. 3, pp. 499–505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. W. F. Anderson, P. S. Rosenberg, A. Prat, C. M. Perou, and M. E. Sherman, “How many etiological subtypes of breast cancer: two, three, four, or more?” JNCI Journal of the National Cancer Institute, vol. 106, no. 8, p. dju165, 2014. View at Publisher · View at Google Scholar
  18. Z. I. Hu and H. L. McArthur, “Immunotherapy in breast cancer: the new frontier,” Current breast cancer reports, vol. 10, no. 2, pp. 35–40, 2018. View at Publisher · View at Google Scholar
  19. F. Zhang, Y. Deng, and R. Drabier, “Multiple biomarker panels for early detection of breast cancer in peripheral blood,” BioMed Research International, vol. 2013, Article ID 781618, 7 pages, 2013. View at Publisher · View at Google Scholar
  20. M. Zeeshan, B. Salam, Q. S. Khalid, S. Alam, and R. Sayani, “Diagnostic accuracy of digital mammography in the detection of breast cancer,” Cureus, vol. 10, Article ID e2448, 2018. View at Publisher · View at Google Scholar
  21. H. Li, J. Liu, J. Chen et al., “A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients,” Nature Communications, vol. 9, no. 1, article no. 1614, 2018. View at Publisher · View at Google Scholar
  22. I. Block, M. Burton, K. P. Sørensen et al., “Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancer,” Oncotarget, vol. 9, no. 10, pp. 9030–9042, 2018. View at Publisher · View at Google Scholar
  23. J. Hayes, P. P. Peruzzi, and S. Lawler, “MicroRNAs in cancer: biomarkers, functions and therapy,” Trends in Molecular Medicine, vol. 20, no. 8, pp. 460–469, 2014. View at Publisher · View at Google Scholar
  24. L. Tutar, E. Tutar, and Y. Tutar, “MicroRNAs and cancer; an overview,” Current Pharmaceutical Biotechnology, vol. 15, no. 5, pp. 430–437, 2014. View at Publisher · View at Google Scholar
  25. P. D. Wagner, M. Verma, and S. Srivastava, “Challenges for biomarkers in cancer detection,” Annals of the New York Academy of Sciences, vol. 1022, no. 1, pp. 9–16, 2004. View at Publisher · View at Google Scholar
  26. Y. Shao, X. Sun, Y. He, C. Liu, and H. Liu, “Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer,” PLoS ONE, vol. 10, no. 7, Article ID e0133830, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Chen, H. Pan, Y. Qian, W. Zhou, and X. Liu, “MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2,” Molecular Cancer, vol. 17, no. 1, 2018. View at Publisher · View at Google Scholar
  28. L. Deng, Q. Lei, Y. Wang et al., “Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis,” Oncotarget, vol. 8, no. 65, pp. 108712–108725, 2017. View at Publisher · View at Google Scholar